Exploring the immune-inflammatory mechanism of Maxing Shigan Decoction in treating influenza virus A-induced pneumonia based on an integrated strategy of single-cell transcriptomics and systems biology

Background Influenza is an acute respiratory infection caused by influenza virus.

Maxing Shigan Decoction (MXSGD) is a commonly used traditional Chinese medicine prescription for the prevention and treatment of influenza.

However, its mechanism remains unclear.

Method The mice model of influenza A virus pneumonia was established by nasal inoculation.

After 3 days of intervention, the lung index was calculated, and the pathological changes of lung tissue were detected by HE staining.

Firstly, transcriptomics technology was used to analyze the differential genes and important pathways in mouse lung tissue regulated by MXSGD.

Then, real-time fluorescent quantitative PCR (RT-PCR) was used to verify the changes in mRNA expression in lung tissues.

Finally, intestinal microbiome and intestinal metabolomics were performed to explore the effect of MXSGD on gut microbiota.

Results The lung inflammatory cell infiltration in the MXSGD group was significantly reduced ( p  < 0.05).

The results of bioinformatics analysis for transcriptomics results show that these genes are mainly involved in inflammatory factors and inflammation-related signal pathways mediated inflammation biological modules, etc.

Intestinal microbiome showed that the intestinal flora Actinobacteriota level and Desulfobacterota level increased in MXSGD group, while Planctomycetota in MXSGD group decreased.

Metabolites were mainly involved in primary bile acid biosynthesis, thiamine metabolism, etc.

This suggests that MXSGD has a microbial–gut–lung axis regulation effect on mice with influenza A virus pneumonia.

Conclusion MXSGD may play an anti-inflammatory and immunoregulatory role by regulating intestinal microbiome and intestinal metabolic small molecules, and ultimately play a role in the treatment of influenza A virus pneumonia.